gilead post in-lin total revenue vs non-gaap ep
vs in-lin consensu estim product sale guidanc
tighten y/i think
under-valued cash flow though major re-rat like requir pipelin
program capabl acceler revenu growth
total revenu q/q y/i in-lin consensu
estim overal product sale q/q y/i
ahead world-wide hiv/hbv sale q/q y/i
consensu hcv sale q/q
y/i also consensu gilead indic
adjust taken statutori revenu reserv primarili
impact hiv hcv revenu contribut headwind revenu
compar gilead report non-gaap gross margin vs non-gaap
 sg expens revenu revenu
vs respect gilead report tax rate vs
non-gaap ep q/q y/i in-lin consensu
gilead increas lower end product sale guidanc
y/i gilead also tighten full year guidanc non-
 expens non- sg expens
guidanc gross margin effect tax rate
unchang adjust estim reflect recent trend updat
guidanc product revenu estim increas
non-gaap ep estim decreas dcf-base price target
hiv/hbv sale q/q y/i consensu
gilead busi in-lin estim q/q
y/i vs demand trend remain strong prescript
y/i biktarvi gener q/q revenu sixth full quarter
market biktarvi number one prescrib regimen treatment-na
switch patient nearli half new patient start biktarvi growth
 biktarvi scrip q/q off-set declin prescript gilead hiv
regimen total hiv scrip q/q gilead report taf-
base regimen account gilead hiv prescript volum
hiv sale eu q/q y/i neg impact
statutori rebat sale continu impact avail
truvada gener sever european countri gilead note rate declin
moder due launch descovy-bas mostli biktarvi regimen across europ
biktarvi approv eu june number one prescrib regimen
germani franc spain biktarvi launch itali june juli
avail european market gilead expect launch biktarvi across europ
help off-set impact gener possibl return growth
pleas see page report import disclosur
gilead market leader treatment hiv hcv acquir car-t oncolog
platform kite expect combin launch new taf-bas
combin pill hiv market growth share gain price increas hiv franchis
sale grow compound-annual-growth-rate despit viread patent expir
expect declin gilead hcv franchis moder price patient volum
begin plateau project gilead hcv franchis gener world-wide sale
car-t therapi yescarta adopt standard care r/r dlbcl
project sale grow nearli base dcf analysi gilead stock
under-valued expect cash flow
file fda approv filgotinib ra
data phase iib atla
combo studi nash
data registr studi kte-
mcl
hcv sale
hiv franchis grow
despit expir
rest pipelin product
exce project
launch taf-bas pill allow
hiv franchis grow
expir tenofovir patent
candid pipelin
hcv sale fail achiev forecast
hiv franchis fail meet
project due competit major
chang treatment paradigm
gilead pipelin busi
develop effort fail produc
product capabl drive meaning
revenu earn
gilead develop market treatment hiv hbv hcv inflamm oncolog
gilead antivir portfolio biggest revenu driver gilead lead hiv franchis
anchor tenofovir well-toler efficaci nucleotid analog gilead
stribild genvoya odefsey descovi biktarvi togeth captur share
treatment-na hiv patient drive hiv franchis revenu project
revenu hcv franchis led sofosbuvir nucleosid inhibitor
result phase trial sofosbuvir-bas regimen shown potent
well toler high barrier viral resist expect hcv franchis
maintain approx revenu
prep market continu experi strong growth gilead indic
q/q y/i individu take truvada prep descovi
snda hiv prep grant approv octob convers effort
well underway ahead truvada loe next septemb gilead indic
number prescrib hiv prep much larger hiv treatment approx
prescrib written least one prescript hiv prep howev
half volum account thousand specialist gilead
primari focu gilead assum similar rate convers compar histor switch
tdf taf regimen given specialist experi convers
understand valu descovi renal bone safeti profil
 hcv revenu q/q y/i increas sequenti gilead
note mostli due continu uptak author gener epclusa
partli due neg impact adjust statutori revenu
clawback reserv europ global hcv revenu q/q y/i
manag remain hope stabl predict busi go forward
slow steadi declin hcv market patient start
gilead record q/q y/i revenu yescarta eighth full quarter
market consensu estim
yescarta first quarter gilead record q/q y/i sale
yescarta gilead indic call high rate clinic trial usag
among elig patient may quarterli fluctuat
yescarta sale futur effort remain identif appropri
patient educ provid yescarta clinic profil gilead continu
work improv medicar reimburs access patient year
age payment increas reimburs medicar
patient went effect octob cancer center author
treat patient across europ
yescarta approv eu august gilead continu add certifi site
europ obtain reimburs germani franc spain gilead
record q/q intern sale yescarta anticip
european approv yescarta gilead previous leas manufactur facil
netherland come on-lin yescarta revenu
gilead previous guid increment impli nearli
doubl revenu compar launch continu ramp
yescarta expand european market base current trend cut
yescarta estim assum increment
revenu y/i gener consist prior guidanc
clinic trial yescarta continu pivot phase studi dlbcl
complet enrol gilead share three-year surviv data analysi
earli steroid intervent well data registr
studi construct yescarta differ manufactur
gilead expect begin clinic develop allogen car-t therapi
gilead also develop cell therapi solid tumor indic
phase ia solid tumor cervic head neck phase
ia solid tumor bladder urotheli nsclc complet
enrol
filgotinib phase finch program rheumatoid arthriti demonstr competit
efficaci profil potenti best-in-class safeti profil among jak inhibitor ra
filgotinib current file eu japan gilead reiter call
commit file ye phase trial on-going ulcer coliti
crohn diseas data anticip
expect complet enrol gilead recent
initi two phase studi filgotinib psoriat arthriti plan initi phase
develop ankylos spondyl call gilead indic phase
ii studi evalu filgotinib cutan lupu erythematosu sjgren syndrom
fail meet primari endpoint though filgotinib appear activ
patient activ diseas gilead disclos result trial plan
develop indic later date
gilead continu emphas regard thrombosi risk ra filgotinib
potenti best-in-class jak inhibitor set gilead seem conserv
expect label perspect fda like appli class warn
thrombosi risk jak inhibitor ra current market member
class filgotinib get approv howev gilead invest resourc
educ physician filgotinib competit clinic profil order ensur robust
launch competit market model launch filgotinib
project revenu gilead
investor wait gilead revenu stabil three year declin
gilead updat guidanc impli revenu growth y/i suggest
fact trough revenu year expect gilead hcv busi
continu contract becom rel minor part gilead top-lin
launch taf regimen gilead hiv franchis continu
bright spot anticip y/i growth appear capabl compens
hcv trend well loss exclus letairi ranexa gilead
weather recent competit hiv launch discern impact leadership
posit seem safe next sever year therefor day precipit declin
gilead revenu appear past revenu growth may excit
also terrifi sometim bore good gilead continu under-valued
project cash flow dcf-base price target remain nonetheless
hiv franchis also face patent expiri next sever year gilead
prospect long-term top-lin growth appear middl fact project
product sale compound-annual-growth-rate gilead recent expans glpg collabor add new
candid larg market pipelin step right direct though risk
candid remain none yet proven like blockbust
suspect major re-rat share requir better visibl pipelin candid
capabl drive meaning reacceler revenu
gilead develop market treatment hiv hbv hcv inflamm cancer
gilead antivir portfolio largest revenu driver next sever year
gilead lead hiv franchis anchor tenofovir well-toler efficaci
nucleotid analog gilead hiv franchis gener
revenu captur share patient newli initi hiv therapi
tenofovir disoproxil fumar viread lost patent protect gilead develop
second-gener version tenofovir alafenamid taf improv safeti
extend patent protect project sale gilead hiv franchis grow
launch new patent-protect combin pill
biktarvi bic/f/taf genvoya e/c/f/taf descovi f/taf odefsey e/r/taf
taf regimen extend commerci life franchis gilead hcv franchis
built around sofosbuvir nucleosid inhibitor whose potenc high barrier
resist made cornerston market-lead all-or hcv combin
sovaldi sofosbuvir launch decemb eu januari
approv gilead harvoni sofosbuvir ledispavir octob
brought first fda-approv interferon-fre regimen genotyp hcv patient
largest hcv popul hcv franchis got fast start
post revenu unfortun best day gilead hcv
franchis past emerg competit gilead hcv franchis gener
revenu estim continu declin gilead
recent expand oncolog franchis acquisit kite gilead
gain yescarta car-t therapi anhl approv fda
octob well lead car-t platform cowen project yescarta achiev
nearli revenu third line anhl gilead emerg inflamm
franchis led filgotinib potent select inhibitor filgotinib
produc impress result phase ii trial rheumatoid arthriti ra crohn
diseas three phase studi ra think filgotinib revenu
potenti ra alon world-wide launch like hope
gilead trough earn final sight three year rapid declin
hcv revenu project non-gaap ep
ep grow compound-annual-growth-rate current trade forward pe
project cash flow yield base dcf analysi gilead stock
under-valued expect cash flow
file fda approv filgotinib rheumatoid arthriti
initi ph ii/iii studi capsid inhibitor highli treatment experienc patient
initi ph ii studi capsid inhibitor treatment-nav patient
data phase iib atla combin studi firsocostat and/or cilofexor nash
data phase ii studi selgatolimod hbv
initi phase ii studi uc
primari analysi yescarta studi cohort evalu earli steroid intervent
data registr studi mcl
data phase phase i/ii studi cll
submit descovi prep
initi phase studi filgotinib ankylos spondyl
data pivot phase ii yescarta indol nhl
data phase i/ii combin studi yescarta atezolizumab
preliminari data phase combin studi yescarta utomilumab
complet enrol phase ii yescarta line high-risk dlbcl
complet enrol ph ia mage solid tumor bladder urotheli nsclc
complet enrol ph ia solid tumor cervic head neck
data filgotinib select phase studi uc
complet enrol filgotinib divers phase studi crohn diseas
initi clinic studi allogen
complet enrol phase cilofexor psc
data phase hbv
cowen compani
cowen compani
total hiv total hcv ranexa product contract comp in-process acquisit cost total sale asset interest net income/ loss incom loss attribut non-controlling net fa net income/ loss ex fa forma ep ex fa share cowen
cowen compani
total hiv total hcv ranexa duct contract incom loss attribut non-controlling fa income/ loss ex fa forma ep ex fa share cowen
statement flow mm
cowen compani
depreci amort stock comp tax benefit employe stock chang net work capit ex cash provid use oper purchas /sale/matur market capit issuanc note acquisit net cash cash provid use invest proce issuanc of/ repurchas common proce issuanc of/ repurchas payment cash provid financ exchang rate chang increas decreas cash cash cash equival begin cash equival end summari oper exclud non-recur item cowen
cowen compani
financi year growth growth growth growth ranexa contract tax asset utilizedtax ratetax payment debtapprox free year growth ratetermin valu termin valu balanc dilut share per fulli dilut valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
gilead develop commerci drug number indic includ hiv hcv
hbv influenza cancer pulmonari hypertens forecast sale product
difficult outlook could alter new safety/efficaci find emerg
competit alter medic treatment paradigm chang pricing/
reimburs environ gilead stock price could also impact chang
outlook key pipelin program evalu market potenti drug
yet approv particularli riski moreov market exclus
gilead franchis depend patent subject challeng gener
drugmak valu gilead franchis could diminish lose
protect key patent
